By Josh White
Date: Friday 06 Jan 2023
(Sharecast News) - Cancer therapy developer BiVictriX Therapeutics announced on Friday that Dr Michael Kauffman has been appointed as its non-executive chairman.
By Josh White
Date: Wednesday 07 Dec 2022
(Sharecast News) - Cancer therapy-focussed biotechnology company BiVictriX Therapeutics has identified a development lead for its 'BVX001' programme, it announced on Wednesday.
By Josh White
Date: Monday 11 Jul 2022
(Sharecast News) - Biotechnology company BiVictriX Therapeutics updated the market on its pipeline on Monday, reporting "significant progress" with its lead candidate, 'BVX001'.
Currency | UK Pounds |
Share Price | 14.00p |
Change Today | 0.000p |
% Change | 0.00 % |
52 Week High | 25.50 |
52 Week Low | 14.00 |
Volume | 2,036,531 |
Shares Issued | 66.12m |
Market Cap | £9.26m |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income | ![]() |
---|
Growth | ![]() |
---|
No dividends found |
Time | Volume / Share Price |
15:10 | 2,036,498 @ 14.00p |
13:13 | 13 @ 15.00p |
13:13 | 10 @ 15.00p |
13:13 | 10 @ 15.00p |
You are here: research